Anti-human CCL24 monoclonal antibody (CM-101)

BIOLOGICAL2 trials

Sponsors

ChemomAb Ltd.

Conditions

HealthyPrimary Sclerosing Cholangitis

Phase 1

Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

CompletedNCT06025851

ChemomAb Ltd.Healthy

Start: 2017-07-24End: 2018-02-18Updated: 2023-09-11

Phase 2

CM-101 in PSC Patients -The SPRING Study

CompletedNCT04595825

ChemomAb Ltd.Primary Sclerosing Cholangitis

Start: 2020-10-01End: 2025-01-10Updated: 2026-07-02

Related Papers

Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies.

2024-06-017 citations